Like IDO-1, high expression of TDO-2 was also associated with worse prognosis (Supplementary Figure 2), such as in low-grade glioma, clear cell renal cancer, papillary renal cancer, acute myeloid leukemia, mesothelioma, and testicular germ cell tumor. Here, TDO2 is linked to central nervous system cancer.